Why the study?
Does varenicline increase the risk of neuropsychiatric adverse events compared to placebo, bupropion, or nicotine replacement therapy in patients attempting smoking cessation?
Does varenicline increase the risk of neuropsychiatric adverse events compared to placebo, bupropion, or nicotine replacement therapy in patients attempting smoking cessation?
Varenicline is highly effective for smoking cessation and does not increase the risk of serious neuropsychiatric adverse events compared to placebo, bupropion, or nicotine replacement therapy, even in patients with a history of psychiatric disorders.
No takes yet. Share an insight, caveat, or question.
Supports first-line varenicline use for cessation; confirms neuropsychiatric safety across RCTs and real-world data.
Gibbons et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: